JHJiaLi C. Huang

JiaLi C. Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


JiaLi C. Huang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding the Cancer-Associated Fibroblast (CAF) and Its Biomarker Fibroblast Activation Protein (FAP), and Aspects in Human Liver Cancer

    by Yiqun Amy Qu, JiaLi C. Huang, Ziqi V. Wang, Angela L. Ferguson, Jasmine Minh Hang Nguyen, MingChang Zhang, Katharine A. Osborne, Badwi B. Boumelhem, Geoffrey W. McCaughan, Ken Liu, et al.

    Tumours contain many fibroblasts, endothelial cells, and leukocytes that are emerging as therapeutic targets complementary to targeting genetically unstable cancer cells. Immunotherapies directed towards this tumour microenvironment (TME) are increasingly effective. Targeting the endothelium has shown success, particularly in hepatocellular carcinoma (HCC). Cancer-associated fibroblasts (CAFs) are also attracting novel nascent therapeutic approaches, and fibroblast activation protein (FAP), which is specific to activated mesenchyme, is prominent amongst CAF markers. This review places emphasis upon FAP, human HCC, and FAP-targeting approaches for therapeutic benefit, including FAP inhibitors, radioligand therapy, T cell and antibody-dependent cytotoxicity/immunotherapy, and FAP-activated prodrugs.